Avalon Globocare Corp
ALBT2.259USD
+0.099+4.58%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
3.73MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Avalon Globocare Corp Unternehmen
Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering transformative, precision diagnostics and clinical laboratory services. The Company offers diagnostic testing utilizing proprietary technology to deliver genetics-driven results. It operates through two segments: Real property rental and Lab Services MSO. Lab Services MSO segment is focused on delivering services related to toxicology and wellness testing and provides a portfolio of diagnostic tests including drug testing, toxicology, and a range of test services, from general bloodwork to anatomic pathology, and urine toxicology. Its capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, and sexually transmitted disease testing. The Lab Services MSO segment is also focused on the commercialization of genetic-based proprietary testing. It is also exploring the commercialization and development of a versatile breathalyzer system, KetoAir breathalyzer.
Unternehmensinformationen
BörsenkürzelALBT
Name des UnternehmensAvalon Globocare Corp
IPO-datumFeb 22, 2016
CEODr. David Jin, M.D., Ph.D.
Anzahl der mitarbeiter5
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 22
Addresse- -
Stadt- -
BörseNASDAQ Capital Market Consolidated
Land- -
Postleitzahl- -
Telefon- -
Website- -
BörsenkürzelALBT
IPO-datumFeb 22, 2016
CEODr. David Jin, M.D., Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Wenzhao (Daniel) Lu
Mr. Wenzhao (Daniel) Lu
Chairman of the Board of Directors
Chairman of the Board of Directors
238.93K
--
Dr. David Jin, M.D., Ph.D.
Dr. David Jin, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
103.00K
--
Ms. Meng Li
Ms. Meng Li
Chief Operating Officer, Company Secretary
Chief Operating Officer, Company Secretary
34.33K
--
Ms. Lourdes Felix
Ms. Lourdes Felix
Independent Director
Independent Director
--
--
Mr. William B. Stilley, III
Mr. William B. Stilley, III
Independent Director
Independent Director
--
--
Ms. Luisa Ingargiola
Ms. Luisa Ingargiola
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Wilbert J. (Billy) Tauzin, II
Mr. Wilbert J. (Billy) Tauzin, II
Director
Director
--
--
Dr. The Hon. Tevi Troy, Ph.D.
Dr. The Hon. Tevi Troy, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven Andrew Sanders, J.D.
Mr. Steven Andrew Sanders, J.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Wenzhao (Daniel) Lu
Mr. Wenzhao (Daniel) Lu
Chairman of the Board of Directors
Chairman of the Board of Directors
238.93K
--
Dr. David Jin, M.D., Ph.D.
Dr. David Jin, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
103.00K
--
Ms. Meng Li
Ms. Meng Li
Chief Operating Officer, Company Secretary
Chief Operating Officer, Company Secretary
34.33K
--
Ms. Lourdes Felix
Ms. Lourdes Felix
Independent Director
Independent Director
--
--
Mr. William B. Stilley, III
Mr. William B. Stilley, III
Independent Director
Independent Director
--
--
Ms. Luisa Ingargiola
Ms. Luisa Ingargiola
Chief Financial Officer
Chief Financial Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jul 2
Aktualisiert: Wed, Jul 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Lu (Wenzhao)
6.89%
Jin (David)
2.97%
Vision Capital NY, Inc.
2.88%
Li (Meng)
0.99%
Equitable Holdings, Inc.
0.41%
Other
85.86%
Aktionäre
Aktionäre
Anteil
Lu (Wenzhao)
6.89%
Jin (David)
2.97%
Vision Capital NY, Inc.
2.88%
Li (Meng)
0.99%
Equitable Holdings, Inc.
0.41%
Other
85.86%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
12.77%
Corporation
3.38%
Investment Advisor
0.57%
Other
83.27%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
37
494.33K
14.25%
+85.00K
2025Q1
39
494.33K
24.18%
+84.18K
2024Q4
39
426.83K
39.01%
+28.37K
2024Q3
38
465.14K
44.22%
+32.28K
2024Q2
37
431.58K
58.50%
+7.86K
2024Q1
35
421.26K
56.90%
-5.41K
2023Q4
36
425.06K
58.60%
-685.00
2023Q3
43
423.55K
58.41%
-5.26K
2023Q2
52
423.10K
61.82%
-6.80K
2023Q1
75
458.47K
67.74%
-1.02K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Lu (Wenzhao)
238.93K
11.69%
+9.00
+0.00%
Mar 31, 2025
Jin (David)
103.00K
5.04%
--
--
Mar 31, 2025
Vision Capital NY, Inc.
100.00K
4.89%
+100.00K
--
Mar 31, 2025
Li (Meng)
34.33K
1.68%
+1.00
+0.00%
Mar 31, 2025
Equitable Holdings, Inc.
14.22K
0.7%
+14.22K
--
Mar 31, 2025
UBS Financial Services, Inc.
2.56K
0.13%
-3.12K
-54.92%
Mar 31, 2025
Tauzin (Wilbert J II)
1.04K
0.05%
+1.04K
--
Mar 31, 2025
Northern Trust Investments, Inc.
121.00
0.01%
+121.00
--
Dec 31, 2023
BofA Global Research (US)
106.00
0.01%
+100.00
+1666.67%
Mar 31, 2025
SBI Securities Co., Ltd.
7.00
0%
-101.00
-93.52%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Oct 24, 2024
Merger
15<1
Oct 24, 2024
Merger
15<1
Oct 24, 2024
Merger
15<1
Oct 24, 2024
Merger
15<1
Jan 04, 2023
Merger
10<1
Jan 04, 2023
Merger
10<1
Datum
Art
Verhältnis
Oct 24, 2024
Merger
15<1
Oct 24, 2024
Merger
15<1
Oct 24, 2024
Merger
15<1
Oct 24, 2024
Merger
15<1
Jan 04, 2023
Merger
10<1
Jan 04, 2023
Merger
10<1
Jan 04, 2023
Merger
10<1
Jan 04, 2023
Merger
10<1
